|
|
|
|
LEADER |
00000cam a2200000 i 4500 |
001 |
SCIDIR_ocn945658059 |
003 |
OCoLC |
005 |
20231120112100.0 |
006 |
m o d |
007 |
cr cnu---unuuu |
008 |
160329s2016 enk ob 001 0 eng d |
040 |
|
|
|a OPELS
|b eng
|e rda
|e pn
|c OPELS
|d N$T
|d YDXCP
|d EBLCP
|d IDEBK
|d OCLCF
|d CDX
|d DEBSZ
|d OCLCQ
|d U3W
|d D6H
|d WYU
|d OCLCQ
|d LVT
|d UX1
|d OCLCO
|d OCLCQ
|d OCLCO
|
019 |
|
|
|a 945641459
|a 945752315
|a 946310361
|a 1066624168
|a 1229762133
|a 1235118423
|
020 |
|
|
|a 9780323428866
|q (electronic bk.)
|
020 |
|
|
|a 032342886X
|q (electronic bk.)
|
020 |
|
|
|z 9780323428637
|
020 |
|
|
|z 0323428630
|
035 |
|
|
|a (OCoLC)945658059
|z (OCoLC)945641459
|z (OCoLC)945752315
|z (OCoLC)946310361
|z (OCoLC)1066624168
|z (OCoLC)1229762133
|z (OCoLC)1235118423
|
050 |
|
4 |
|a R857.N34
|
072 |
|
7 |
|a HEA
|x 012000
|2 bisacsh
|
072 |
|
7 |
|a HEA
|x 020000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 004000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 101000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 109000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 029000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 040000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 092000
|2 bisacsh
|
082 |
0 |
4 |
|a 610.28
|2 23
|
245 |
0 |
0 |
|a Nanobiomaterials in cancer therapy :
|b applications of nanobiomaterials /
|c edited by Alexandru Mihai Grumezescu.
|
264 |
|
1 |
|a Oxford :
|b William Andrew, an imprint of Elsevier,
|c 2016.
|
300 |
|
|
|a 1 online resource
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
0 |
|
|a Applications of nanobiomaterials ;
|v volume 7
|
588 |
0 |
|
|a Online resource; title from PDF title page (EBSCO, viewed March 31, 2016)
|
520 |
|
|
|a Nanobiomaterials in Cancer Therapy presents the major applications of nanobiomaterials in oncology, offering an up-to-date overview of the latest research in this field. Utilizing nanobiomaterials, novel therapeutic approaches enable significant improvements in drug-loading capacity, formulation stability and drug efficiency. In this book, leading researchers from around the world share their expertise and unique insights. The book covers the fabrication methods of platforms for multimodal and combinatorial therapeutic options, along with simultaneous and real-time cancer imaging, and innovative approaches for oncology by passive or active pathways of multifunctional nanocarriers. The work also classifies and discusses engineered nanobiosystems for cancer therapy, prevention, and low cancer recurrence or relapse. This book will be of interest to postdoctoral researchers, professors and students engaged in the fields of materials science, biotechnology and applied chemistry. It will also be highly valuable to those working in industry, including pharmaceutics and biotechnology companies, medical researchers, biomedical engineers and advanced clinicians.
|
504 |
|
|
|a Includes bibliographical references and index.
|
505 |
0 |
|
|a Front Cover; Nanobiomaterials in Cancer Therapy; Copyright Page; Contents; List of contributors; Preface of the series; Preface; About the Series (Volumes I-XI); About Volume VII; 1 Nanopreparations for skin cancer therapy; 1.1 Introduction; 1.2 Skin Morphology; 1.3 Types of Cancer; 1.4 Non-Melanoma Skin Cancer; 1.5 Melanoma Skin Cancer; 1.6 Penetration Pathways of Skin; 1.7 Drug Delivery Systems Applied to Skin Cancer Treatment; 1.8 Liposomes; 1.9 Nanoemulsions and Nanosuspensions; 1.10 Polymeric Nanoparticles; 1.11 Lipid Nanoparticles; 1.12 Dendrimers; 1.13 Photodynamic Therapy
|
505 |
8 |
|
|a 1.14 ConclusionsReferences; 2 Silver nanoparticles in cancer therapy; 2.1 Introduction; 2.2 Silver Nanoparticles; 2.3 Synthesis; 2.3.1 Chemical Synthesis; 2.3.2 Physical Synthesis; 2.3.3 Biological Synthesis; 2.3.3.1 Silver nanoparticles synthesized by bacteria; 2.3.3.2 Silver nanoparticles synthesized by fungi; 2.3.3.3 Silver nanoparticles synthesized by plants; 2.4 Shape; 2.5 Silver Nanoparticles-Cancer Diagnosis and Treatment Applications; 2.5.1 Leukemia; 2.5.2 Breast Cancer; 2.5.3 Lung Cancer; 2.5.4 Prostate Cancer; 2.5.5 Hepatic Cancer; 2.5.6 Cervical Cancer; 2.5.7 Skin Cancer
|
505 |
8 |
|
|a 2.5.8 Larynx Cancer2.5.9 Colon Cancer; 2.6 Conclusions; References; 3 Nanobiomaterials in cancer therapy; 3.1 Introduction; 3.2 The Enhanced Permeability and Retention (EPR) Effect; 3.3 Nanomaterials in Cancer Therapy; 3.3.1 Inorganic NPs; 3.3.1.1 Quantum dots; 3.3.1.2 Magnetic NPs; 3.3.2 Organic NPs; 3.3.2.1 Liposomes; 3.3.2.2 Polymeric micelles; 3.3.2.3 Dendrimers; 3.4 Chemotherapy-Based Nanoformulations; 3.4.1 Doxorubicin; 3.4.2 Paclitaxel; 3.4.3 Cisplatin; 3.4.4 Docetaxel; 3.4.5 Nanotetrac; 3.5 Multifunctional NPs; 3.5.1 Delivery of siRNA and shRNA Complexes; 3.5.2 Active Targeting
|
505 |
8 |
|
|a 3.6 Cancer Therapy Using Natural Products: Nanochemoprevention3.6.1 EGCG; 3.6.2 Resveratrol; 3.6.3 Curcumin; 3.7 Cancer Stem Cells: A Nanotechnology Perspective; 3.8 Conclusions; References; 4 Advances in nanobiomaterials for oncology nanomedicine; 4.1 Introduction; 4.2 Organic Nanobiomaterials; 4.2.1 Liposomes; 4.2.2 Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC); 4.2.3 Polymeric Nanocapsules and Nanospheres; 4.3 Inorganic Nanobiomaterials; 4.3.1 Mesoporous Silica Nanoparticles (MSNs); 4.3.2 Spherical Nucleic Acid Nanoparticles (SNA-NPs)
|
505 |
8 |
|
|a 4.3.3 Boron Nitride Nanotubes (BNNTs)4.4 Combination of Nanotechnology with Photodynamic Therapy to Improve Cancer Treatment; 4.5 Toxicity and Risk Management; 4.6 Conclusions; Acknowledgments; References; 5 Nanobiomaterials: Emerging platform in cancer theranostics; 5.1 Introduction; 5.2 Theranostics and Nanomedicine; 5.2.1 Gold Nanoparticles; 5.2.2 Iron Oxide Nanoparticles in Cancer Theranostics; 5.2.3 Superparamagnetic Iron Oxide Nanoparticles; 5.2.4 Carbon Nanotubes; 5.2.5 Quantum Dots; 5.2.6 Dendrimers; 5.2.7 Vesicular Systems; 5.2.7.1 Liposomes; 5.2.7.2 Polymerosomes
|
650 |
|
0 |
|a Nanomedicine.
|
650 |
|
0 |
|a Cancer
|x Treatment.
|
650 |
|
0 |
|a Nanobiotechnology.
|
650 |
|
0 |
|a Biomedical materials.
|
650 |
|
2 |
|a Nanomedicine
|0 (DNLM)D050997
|
650 |
|
6 |
|a Cancer
|x Traitement.
|0 (CaQQLa)201-0004693
|
650 |
|
6 |
|a Nanobiotechnologie.
|0 (CaQQLa)000286131
|
650 |
|
6 |
|a Biomat�eriaux.
|0 (CaQQLa)201-0025723
|
650 |
|
6 |
|a Nanom�edecine.
|0 (CaQQLa)201-0448752
|
650 |
|
7 |
|a HEALTH & FITNESS
|x Holism.
|2 bisacsh
|
650 |
|
7 |
|a HEALTH & FITNESS
|x Reference.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Alternative Medicine.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Atlases.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Essays.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Family & General Practice.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Holistic Medicine.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Osteopathy.
|2 bisacsh
|
650 |
|
7 |
|a Biomedical materials
|2 fast
|0 (OCoLC)fst00832586
|
650 |
|
7 |
|a Cancer
|x Treatment
|2 fast
|0 (OCoLC)fst00845538
|
650 |
|
7 |
|a Nanobiotechnology
|2 fast
|0 (OCoLC)fst01894713
|
650 |
|
7 |
|a Nanomedicine
|2 fast
|0 (OCoLC)fst01744350
|
700 |
1 |
|
|a Grumezescu, Alexandru Mihai,
|e editor.
|
776 |
0 |
8 |
|i Print version:
|t Nanobiomaterials in cancer therapy.
|d Oxford : William Andrew, an imprint of Elsevier, 2016
|z 9780323428637
|z 0323428630
|w (OCoLC)932174426
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780323428637
|z Texto completo
|